Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production

John Mascarenhas(Tisch Hospital), Ronald Hoffman(Icahn School of Medicine at Mount Sinai), Rami S. Komrokji(Moffitt Cancer Center), Moshe Talpaz(University of Michigan), Rupali Bhave(Atrium Health Wake Forest Baptist), Lilian Varricchio(Icahn School of Medicine at Mount Sinai), Noushin Farnoud(Memorial Sloan Kettering Cancer Center), Lonette Sandy(Icahn School of Medicine at Mount Sinai), Aaron T. Gerds(Cleveland Clinic), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Carolyn Mead‐Harvey(Mayo Clinic in Arizona), Heidi Kosiorek(Mayo Clinic in Florida), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Vesna Najfeld, Andrew Kuykendall(Moffitt Cancer Center), Rona Singer Weinberg(University of North Carolina at Chapel Hill), Jeanne Palmer(Mayo Clinic), Anna Ritá Migliaccio(Altius Institute for Biomedical Sciences), Kristen Pettit(University of Michigan), Marina Kremyanskaya(Tisch Cancer Institute), Frank Fabris(Icahn School of Medicine at Mount Sinai), Abdulraheem Yacoub(The University of Kansas Cancer Center), Juan Arango Ossa(Memorial Sloan Kettering Cancer Center), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Dylan Domenico(Memorial Sloan Kettering Cancer Center), Agapito Gonzalez(The University of Texas at San Antonio Health Science Center), Amy Kong(Icahn School of Medicine at Mount Sinai), Erin McGovern, Amylou C. Dueck(Mayo Clinic in Arizona), Kathryn Johnson(Harvard University), Mikaela Doughtery(Icahn School of Medicine at Mount Sinai)
Blood
November 5, 2021
Cited by 16


Related Papers